Progress in the Study of the Hepatoprotective Effect of SGLT2i on NAFLD Patients with T2DM
Progress in the Study of the Hepatoprotective Effect of SGLT2i on NAFLD Patients with T2DM作者机构：Department of Gastrosenterology First Hospital of Yangtze University Jingzhou China Digestive Disease Research Institution of Yangtze University Jingzhou China Clinical Medical College Yangtze University Jingzhou China
出 版 物：《Journal of Biosciences and Medicines》 (生物科学与医学（英文）)
年 卷 期：2024年第12卷第1期
页 面：115-125页
学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学]
主 题：Sodium-Glucose Cotransporter-2 Inhibitors Non-Alcoholic Fatty Liver Disease Diabetes Mellitus
摘 要：In recent years, the progress of NAFLD has become an important health problem, and the prevention or delay of progress in NAFLD is a major key point. Whether or not to combine T2MD, people are interested in the mechanisms and efficacy of SGLT2i for NAFLD. In this review, we summarized the current clinical research on SGLT2i for the combination of T2MD’s NAFLD patients, and the latest evidence of external or animal experiments. These evidences will help us to more accurately understand the protective effects of SGLT2i in NAFLD. Lifestyle changes are still essential to prevent and treat NAFLD, and for all kinds of drugs that treat NAFLD in clinical trials, SGLT2i may be one of the promising treatments.
维普期刊数据库